FDA Approves Childhood Epilepsy Drugs

Seizure medications authorized for patients 2 years and older.

On Monday, the Food and Drug Administration approved a treatment for seizures in patients two years old and above. The new approval of Fintepla is for the treatment of Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy. The drug was already approved to treat Davet syndrome (DS) another form of childhood-onset epilepsy.

The FDA also approved Ztalmy earlier this month to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. FDA officials explained, “CDD is a rare developmental epileptic encephalopathy (dysfunction of the brain) caused by CDKL5 gene mutations.”

As the Lord Leads, Pray with Us…

  • For FDA researchers and scientists as they review and study medications for authorization.
  • For the children who suffer from epilepsy and other disorders that cause seizures.

Sources: Reuters, PR Newswire, Food and Drug Administration


Back to top